MDxHealth SA (NASDAQ:MDXH) Shares Acquired by Perkins Capital Management Inc.

Perkins Capital Management Inc. grew its position in shares of MDxHealth SA (NASDAQ:MDXH) by 70.7% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 747,375 shares of the company’s stock after purchasing an additional 309,500 shares during the quarter. MDxHealth makes up about 1.5% of Perkins Capital Management Inc.’s portfolio, making the stock its 18th biggest holding. Perkins Capital Management Inc. owned 0.48% of MDxHealth worth $1,555,000 at the end of the most recent reporting period.

MDxHealth Price Performance

Shares of MDXH opened at $2.08 on Thursday. MDxHealth SA has a 12 month low of $1.95 and a 12 month high of $4.64. The stock’s 50 day moving average is $2.31 and its two-hundred day moving average is $2.59.

MDxHealth (NASDAQ:MDXH) last released its quarterly earnings results on Wednesday, November 6th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.27) by ($0.13). The company had revenue of $23.32 million during the quarter, compared to analyst estimates of $21.48 million. MDxHealth had a negative net margin of 50.54% and a negative return on equity of 987.86%. On average, analysts forecast that MDxHealth SA will post -1.16 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, Lake Street Capital began coverage on shares of MDxHealth in a research report on Thursday, October 31st. They set a “buy” rating and a $7.00 price target on the stock.

MDxHealth Profile

MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. Its testing solutions includes Select mdx, a non-invasive urine test for prostate cancer that measures the expression of two mRNA cancer-related biomarkers; Confirm mdx for prostate cancer tissue test that validates epigenetic test that guides the detection of occult prostate cancer on a patient's previously biopsied negative tissue; and Resolved mdx for urinary tract infection that identifies personalized effective antibiotic options against the patient's infection.